Department of Research and Development, Héma-Québec, Québec, Canada.
Clin Immunol. 2011 Dec;141(3):273-83. doi: 10.1016/j.clim.2011.06.009. Epub 2011 Jul 8.
Activation of self-reactive CD4(+) T cells plays a central role in the initiation and maintenance of autoimmune diseases. We recently reported that intravenous immunoglobulin (IVIg) inhibits the MHC II-restricted CD4(+) T cell activation induced by the presentation of immune complexes. Because native antigens can also play a role in the induction of several autoimmune diseases, we determined whether IVIg could also affect CD4(+) T cell activation following presentation of native antigens by APCs. Here we report that IVIg significantly reduces the activation of CD4(+) T cells by native ovalbumin. The inhibitory effect is FcγR-independent and occurs following internalization of IVIg inside APCs, where it interferes with the intracellular events leading to MHC II-dependent antigen presentation. The effect of IVIg on native antigen presentation could therefore contribute to dampen the autoimmune reaction by reducing CD4(+) T cell activation and the subsequent inflammatory response induced by these cells.
自身反应性 CD4(+) T 细胞的激活在自身免疫性疾病的起始和维持中起着核心作用。我们最近报道称,静脉注射免疫球蛋白 (IVIg) 可抑制由免疫复合物呈递引起的 MHC II 限制性 CD4(+) T 细胞激活。因为天然抗原也可能在几种自身免疫性疾病的诱导中发挥作用,所以我们确定 IVIg 是否也可以影响 APC 呈递天然抗原后 CD4(+) T 细胞的激活。在这里,我们报告称 IVIg 可显著降低天然卵清蛋白诱导的 CD4(+) T 细胞的激活。这种抑制作用不依赖于 FcγR,并且发生在 IVIg 在内皮细胞内内化之后,在那里它干扰导致 MHC II 依赖性抗原呈递的细胞内事件。因此,IVIg 对天然抗原呈递的作用可以通过减少 CD4(+) T 细胞激活以及这些细胞诱导的随后的炎症反应来减轻自身免疫反应。